Thyroid function and autoimmunity during interferon β-1b treatment: A multicenter prospective study

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3525-3532

  Durelli, Luca ^a   Ferrero, Bruno ^a   Oggero, Alessandra ^a   Verdun, Elisabetta ^a   Ghezzi, Angelo ^b,i   Montanari, Enrico ^c,h   Zaffaroni, Mauro ^b,i   Trojano, M ^d   Giuliani, F ^d   Salvi, F ^e   Stecchi, S ^f   Reggio, A ^g   Reggio, E ^g   Negri, G ^h   Ludovico, L ^h   Mancardi, G L ^j   Inglese, M ^j   Carolei, A ^k   Totaro, R ^k   Milanese, C ^l   La Mantia, L ^l   Caputo, D ^m   Mini, M ^m   Cotrufo, R ⁿ   Lus, G ⁿ   Cosi, V ^o   Romani, A ^o   Gallai, V ^p   Sarchielli, P ^p   Nocentini, U ^q   Rizzato, B ^q   Tonali, P A ^r   Massaro, A R ^r   Rosati, G ^s   Sotgiu, S ^s   Annunziata, P ^t   Bortolon, F ^h   Stenta, G ^h   Sormani, M P ^u   Beckmann, K ^v   Brossa, P C ^a   Ghigo, E ^a   Maccario, M ^a   Faggiano, F ^a   Ecari, U ^w   Ciampini, M ^w   Barbero, P ^a   Pipieri, A ^a   Ricci, A ^a   Bosio, A ^a   Cucci, M A ^a   Bergamasco, B ^a   Aimo, G ^x   Giorda, L ^x   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale di Gallarate   (Italy)

^c Ospedale di Fidenza   (Italy)

^d Clinica Neurologica   (Italy)

^e BELLARIA HOSPITAL   (Italy)

^f Azienda USL di Bologna   (Italy)

^g Policlinico Universitario   (Italy)

^h Divisione di Neurologia   (Italy)

ⁱ Divisione di Neurologia   (Italy)

^j Clinica Neurologica   (Italy)

^k Clinica Neurologica   (Italy)

^l DEPARTMENT OF NEUROSURGERY   (Italy)

^m Istituto Don Gnocchi   (Italy)

ⁿ Clinica Pediatrics   (Italy)

^o Clinica Neurologica   (Italy)

^p Clinica Neurologica   (Italy)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

^r CATHOLIC UNIVERSITY   (Italy)

^s Clinica Neurologica dell'Univ   (Italy)

^t Clinica Neurologica   (Italy)

^u UNIVERSITY OF GENOA   (Italy)

^v BAYER PHARMA AG   (Germany)

^w Angelini SpA   (Italy)

^x MOLINETTE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; THYROID ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION;

EID: 17944377203     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.8.3525     Document Type: Article

References (48)

1. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis
2. Side effects of α interferon in chronic hepatitis C
3. Side effects of high-dose interferon therapy for chronic hepatitis C
4. Endocrine and neurological adverse effects of the therapeutic interferons
5. The risk factors for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C
6. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: A case-control study
7. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection
8. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection
9. Multiple sclerosis
10. Autoimmune events during interferon β-1b treatment for multiple sclerosis
11. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment
12. Long-term interferon β-1b therapy for MS: Is routine thyroid assessment always useful?
13. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-β therapy for multiple sclerosis
14. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon β-1b
15. Intravenous recombinant interferon-β versus interferon-α-2a and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-α
16. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-β
17. An overview of methods for the analysis of longitudinal data
18. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
19. A radioimmunoassay for measurement of 3′-monoiodothyronine
20. Evaluation of free thyroxine methods in the presence of iodothyronine-binding autoantibodies
21. American Thyroid Association guidelines for detection of thyroid dysfunction
22. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders
23. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
24. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy
25. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy
26. Association of MS with thyroid disorders
27. Autoimmunity in multiple sclerosis
28. Multiple sclerosis and other immunological diseases
29. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis
30. Antithyroid antibodies in multiple sclerosis
31. Thyroid function in multiple sclerosis
32. The spectrum of thyroid disease in a community: The Whickham Survey
33. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey
34. The epidemiology of thyroid disease and implications for screening
35. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: Associations with serum lipids
36. Characterization of the thyroid microsomal antigen, and its relationship to thyroid peroxidase, using monoclonal antibodies
37. Comparison of measurements of in vitro production of antithyroid microsomal antibody versus antithyroid peroxidase antibody
38. Immune-mediated side-effects of cytokines in humans
39. Immunological adverse effects of interferon treatment
40. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
41. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
42. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
43. Interferon β-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
44. The type I interferon receptor: Structure, function and evolution of a family
45. The function of type I interferons in antimicrobial immunity
46. Comparative effects of interferon-consensus 1, interferon-α2a, and interferon-β1b on HLA expression and lymphoproliferation: A preclinical model for treatment of multiple sclerosis
47. Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis
48. 1a in relapsing-remitting multiple sclerosis